Navigation Links
Drug used for blood cancers may stop spread of breast cancer cells, Mayo Clinic finds
Date:8/22/2013

JACKSONVILLE, Fla. A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.

"Treatment with low doses of decitabine in an animal model of breast cancer restored PRKD1 expression, reduced tumor size, and blocked metastasis to the lung," says the study's senior investigator, Peter Storz, Ph.D., a biochemist and molecular biologist at Mayo Clinic in Florida.

"The outcome of patients with invasive breast cancer is less than optimal despite many attempts to improve treatment, including advanced chemotherapy and hormonal therapy," says Dr. Storz. "We hope this study offers a new avenue to prevent breast cancer from becoming aggressive and untreatable."

The research team, which includes first author Sahra Borges, Ph.D., a postdoctoral researcher in Dr. Storz's lab, found that the gene coding for PRKD1 was silenced in all but one subtype of invasive breast cancer, including aggressive triple negative breast cancer. That subtype is invasive lobular carcinoma.

Dr. Borges also developed an assay that can be used to measure the amount of PRKD1 that is silenced in patients' breast tumors.

"Because we found that PRKD1 is increasingly silenced as breast cancer becomes aggressive and spreads, the hope is that this test can be further developed and used to predict which patients are at risk for cancer metastasis, and thus may benefit from decitabine," Dr. Borges says.

Decitabine, approved by the U.S. Food and Drug Administration for use in some blood cancers, is a demethylating agent, meaning that it can switch on beneficial genes such as PRKD1 that cancer has silenced in order to grow.

Treating genes that are silenced is much easier than trying to restore function of a mutated gene, Dr. Storz says. The normal function of PRKD1, which is expressed in cells of the mammary gland, is to maintain normal function by preventing cells from morphing into a state where they can dislodge and spread, he says.

The researchers hope this study will help them to design a clinical trial in collaboration with Mayo Clinic physicians using decitabine to promote re-expression of PRKD1 and agents that activate PRKD1.


'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Marine D3: Review Exposes Anti-Aging & Blood Pressure Supplement
2. Longest and largest study of insulin pumps to treat type 1 diabetes in children shows they control blood sugar more effectively and with fewer complications than injections
3. Blood Pressure Checks Offered at Heritage Woods of Sterling Affordable Assisted Living
4. Study examines risk of severe blood sugar swings among diabetics taking fluoroquinolones
5. Rock River Valley Blood Center Earns AABB Accreditation
6. Hyper-vigilance about race linked to elevated blood pressure in black patients
7. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman Alleges that NuvaRing Use Caused Her to Develop Serious Blood Clot Disorder, Reports Alonso Krangle
8. New NuvaRing Blood-Clotting Lawsuit Allegations Report: Resource4thePeople Updates Latest Legal Developments as Litigation Proceeds
9. Capturing live tumor cells in the blood
10. Foods That Increase Red Blood Cell Production Released at HRWC Blog
11. Latest Yaz, Yasmin Lawsuits Alleging Blood-Clotting Side Effects: Resource4thePeople Reports Consolidated Cases Continue to Be Opened, Settled and Dismissed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Sugar Land, TX (PRWEB) , ... February 12, ... ... the families of southwest Houston and surrounding communities by continuing it’s commitment to ... Fort Bend Family Promise. The organization works closely with area homeless families to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic ... for Health Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ... in big-dollar therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and ...
(Date:2/12/2016)... , ... February 12, 2016 , ... A lot has ... 35 years. A president has access to health and wellness resources most Americans could ... world, no single individual has a schedule as frenetic as the U.S. President. ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... the field of long term care. With that, says Patrick Loughney, president of ... in administrative roles in long term care environments. His company, which offers prep ...
(Date:2/12/2016)... ... ... Planet Future is a Final Cut Pro X themed package ... pictures, videos as well as text in an exciting cartoon environment. Planet Future is ... beautiful frame overlay. Pixel Film Studios makes editing easy; simply insert media into the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Eli Lilly and Company (NYSE: LLY ) ... (pemetrexed disodium) vitamin regimen patent would not presently be infringed ... France , Italy and ... only with dextrose solution.  --> ... of Appeal held that Lilly,s patent would be indirectly infringed ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... -- PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for ... Company also filed its Quarterly Report on Form 10-Q for ... and Exchange Commission today. --> ... --> --> Net sales for the three ... to $5.4 million from $2.8 million for the three months ...
Breaking Medicine Technology: